MabDesign joins EuropaBio: innovation linked to the industrial field of biotherapy

PRESS RELEASE

Brussels, 14 December 2021 – EuropaBio is pleased to announce that MabDesign has joined as an associate member.

MabDesign, the French biotherapy industrial association, aims to support, federate and increase the visibility of the biopharmaceutical industry since the R&D phases until bioproduction and clinical phases, foster exchanges, promote the development and competitiveness of companies, and stimulate innovation by encouraging the emergence of start-ups from academic research.

In order to carry out its development strategy and to adapt to changes in the industrial ecosystem, MabDesign’s governance is composed of DBV Technologies, Lyonbiopole, Pierre Fabre, Sanofi, ABL Europe, bioMérieux, Institut Pasteur, Thermo Fisher Scientific and TreeFrog Therapeutics as well as three Qualified Persons with Nicola Beltramineli (Lysogene), Hervé Broly (Merck) and Stéphane Legastelois (33 California). The diversity of MabDesign’s board of directors allows to closely follow the needs and challenges of the industrial biotherapy sector.

MabDesign currently counts with more than 215 member companies.

EuropaBio Director-General Dr. Claire Skentelbery commented “MabDesign represents the future of European advanced medicines, with an extensive network of companies from start-ups through to multi-nationals. The innovation base and strength of such a community helps EuropaBio to support Europe’s development as a world leader in advanced therapeutics for patients”.

Nicolas Groux, CEO at MabDesign, added: “We are glad to be part of EuropaBio and we believe that by joining the association we can voice up the expertise that our members have and it will contribute to promote exchanges and collaborations at the European level”.

ENDS

Media contact

Dovilé Sandaraitė, Communications Manager

Email: d.sandaraite@europabio.org
About EuropaBio

EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 1800 biotech SMEs. Read more about our work at www.europabio.org.

About MabDesign

MabDesign, the French biotherapy industry association, aims to structure the biopharmaceutical industry in France from its R&D phases to biomanufacturing and marketing. Its objective is also to promote the creation of innovative start-ups resulting from academic research, to increase the visibility of the biopharmaceutical industry, to promote exchanges, to support the development and competitiveness of companies, and to stimulate innovation.

To achieve this objective, MabDesign is setting up a coherent set of actions promoting exchanges, collaborations and the development of skills of the sector's players, as well as supporting companies through tailored studies (intellectual property, innovation financing, market research, marketing & innovation management, business development and monitoring). Operational since September 2015, MabDesign currently has more than 215 member companies, including pharmaceutical and biotech companies, service providers, training organizations, high-tech equipment suppliers and specialized consultants. To know more visit: www.mabdesign.fr